Publications

Search our bibliography using the filters on the right-hand side.

Displaying 151 through 200 of 325 publications.

Alamo-Junquera D, Sunyer J, Iniguez C, Ballester F, Garcia-Esteban R, Forns J, Turner MC, Lertxundi A, Lertxundi N, Fernandez-Somoano A, Rodriquez-Dehli C, Julvez J. Prenatal head growth and child neuropsychological development at age 14 months. Am J Obstet Gynecol. 2015 May;212(5):661e1-e11. doi: 10.1016/j.ajog.2014.12.001

Slota C, Shi A, Chen G, Bevans M, Weng NP. Norepinephrine preferentially modulates memory CD8 T cell function inducing inflammatory cytokine production and reducing proliferation in response to activation. Brain Behav Immun. 2015 May;46:168-79.

Gnanasakthy A, DeMuro C, Lewis S, Tseng B. Development of a disease model for sporadic inclusion body myositis. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.

Brennan VK, Mauskopf JA, Colosia AD, Copley-Merriman K, Hass B, Palencia R. Utility estimates for patients with type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):111-23.

Matharu M, Pascual J, Nilsson Remahl L, Straube A, Johannes C, Odom D, Gutierrez L, Andrews E, Lum A. Interim analysis of the real-world utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in an observational study in the European Union. Poster presented at the International Headache Conference; May 14, 2015. Valencia, Spain. [abstract] Cephalalgia. 2015; 35(6S):39.

Mordin M, Masaquel C, Abbott C, Copley-Merriman C. Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study. BMJ Open. 2014 Oct 16;4(10):e005150. doi: 10.1136/bmjopen-2014-005150

Vilahur N, Fernandez MF, Bustamante M, Ramos R, Forns J, Ballester F, Murcia M, Riano I, Ibarluzea J, Olea N, Sunyer J. In utero exposure to mixtures of xenoestrogens and child neuropsychological development. Environ Res. 2014 Oct;134:98-104. doi: 10.1016/j.envres.2014.07.002

Matharu M, Pascual J, Nilsson Remahl I, Odom D, Gutierrez L, Andrews E, Largent J, Johannes C. EHMTI-0192. Onabotulinumtoxina prophylaxis in chronic migraine utilization and patient characteristics: observational study in the European Union. Poster presented at the 4th European Headache and Migraine Trust International Congress 2014; September 2014. Copenhagen, Denmark. [abstract] J. Headache Pain. 2014 Sep 18; 15(Suppl 1):G24. doi: 10.1186/1129-2377-15-S1-G24

Brennan VK, Colosia AD, Copley-Merriman K, Mauskopf J, Haas B, Psalencia R. Incremental costs associated with myocardial infarction and stroke in patients with type 2 diabetes mellitus: an overview for economic modeling. J Med Econ. 2014 Jul;17(7):469-80. doi: 10.3111/13696998.2014.915847

Luciano JV, Barrada JR, Aguado J, Osma J, García-Campayo J. Bifactor analysis and construct validity of the HADS: a cross-sectional and longitudinal study in fibromyalgia patients. Psychological Assessment. 2014 Jun;26(2):395-406.

Poulos C, Kinter E, Yang JC, Bridges JFP, Posner JD, Reder A. United States multiple sclerosis patients' preferences for injectable treatments. Poster presented at the European Federation of Neurological Sciences - European Neurological Society Joint Congress of European Neurology; May 31, 2014.

Purser MF, Wilson MR, Mladsi DM, Wu Y. Literature review of economic models for the treatment of parkinson's disease. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 2, 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3):A60. doi: 10.1016/j.jval.2014.03.355

Luciano JV, Guallar JA, Aguado J, López-Del-Hoyo Y, Olivan B, Magallón R, Alda M, Serrano-Blanco A, Gili M, García-Campayo J. Effectiveness of group acceptance and commitment therapy for fibromyalgia: a 6-month randomized controlled trial (EFFIGACT study). Pain. 2014 Apr;155(4):693-702.

Forns J, Vegas O, Julvez J, Garcia-Esteban R, Rivera M, Lertxundi N, Guxens M, Fano E, Ferrer M, Grellier J, Ibarluzea J, Sunyer J. Association between child cortisol levels in saliva and neuropsychological development during the second year of life. Stress Health. 2014 Apr;30(2):142-8. doi: 10.1002/smi.2504

Gonzalez JM, Johnson FR, Runken MC, Poulos CM. Evaluating migraineurs' preferences for migraine treatment outcomes using a choice experiment. Headache. 2013 Nov;53(10):1635-50.

Bhattacharyya S, Sacco P, Shirore R, Sonathi V, Thomas SK. A de novo economic model to assess the cost and quality of life consequences of an intervention for levodopa induced dyskinesia amongst patients with Parkinson's disease. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A590-1.

Rouse M, McKenna S, Twiss J, Graham JE, Wilburn J. Quality of life outcomes in multiple sclerosis: a review of the literature. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A626. doi: 10.1016/j.jval.2013.08.1843

Casas L, Torrent M, Zock JP, Doekes G, Forns J, Guxens M, Taubel M, Heinrich J, Sunyer J. Early life exposures to home dampness, pet ownership and farm animal contact and neuropsychological development in 4 year old children: a prospective birth cohort study. Int J Hyg Environ Health. 2013 Nov;216(6):690-7. doi: 10.1016/j.ijheh.2012.12.013

Luciano JV, Aguado J, Serrano-Blanco A, Calandre EP, Rodriguez-Lopez CM. Dimensionality, reliability, and validity of the revised fibromyalgia impact questionnaire in two Spanish samples. Arthritis Care Res (Hoboken). 2013 Oct;65(10):1682-9.

López-León S, Rivero E. Statins for prevention of alzheimer's disease: systematic review and meta-analysis. Poster presented at the 29th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2013. Montreal, Spain.

Marcano Belisario J, Tudor KI, Sumalinog ARN, Middleton LT, Car J. Educational interventions for improving the skills of medical practitioners to detect, diagnose, and manage people with cognitive impairment and dementia (Protocol). Cochrane Database Syst Rev. 2013 Jun 6. doi: 10.1002/14651858.CD010580

Davis KL, Fitzgerald T, Meyers J, Kulkarni A, Svarvar P, Hewitt D. Incidence of adverse treatment effects in parkinson's disease: evidence from a large employer population. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 15, 2013. [abstract] Value Health. 2013 May; 16(3):A100.

Davis KL, Fitzgerald T, Kulkarni A, Meyers J, Svarvar P, Hewitt D. Comparative risk of adverse treatment effects in parkinson's disease: evidence from a large employer population. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 15, 2013. [abstract] Value Health. 2013 May; 16(3):A100.

Davis KL, Fitzgerald TP, Meyers J, Kulkarni A, Svarvar P, Hewitt DJ. Economic burden of adverse treatment effects in parkinson's disease: evidence from a large employer population. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):A103-4.

Gnanasakthy A, DeMuro-Mercon CJ, Clark MJ, Mordin MM, Thomas S. Role of patient-reported outcome measures in the assessment of central nervous system agents. Ther Innov Regul Sci. 2013;47(5):613-8.

Meyers J, Candrilli S, Allen R, Manjunath R, Calloway M. Health care resource utilization and costs associated with restless legs syndrome among managed care enrollees treated with dopamine agonists. Manag Care. 2012 Oct 1;21(10):44-51.

Cohen JT, Marino RJ, Sacco P, Terrin N. Association between the functional independence measure following spinal cord injury and long-term outcomes. Spinal Cord. 2012 Oct;50(10):728-33. doi: 10.1038/sc.2012.50

Chandran AB, Coon CD, Martin SA, McLeod LD, Coles TM, Arnold LM. Sphygmomanometry-evoked allodynia in chronic pain patients with and without fibromyalgia. Nurs Res. 2012 Sep 1;61(5):363-8.

Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.

Mines D, Tennis PS, Curkendall S, Li A, Peterson C, Andrews EB, Calingaert B, Rothman KJ. Topiramate use in pregnancy and risk of oral clefts. Presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug; 21(Suppl 3):320. doi: 10.1111/j.1399-5448.2012.03324.x

Brown TM, Garg S, Chandran AB, McNett M, Silverman SL, Hadker N. The impact of 'best-practice' patient care in fibromyalgia on practice economics. J Eval Clin Pract. 2012 Aug 1;18(4):793-8.

Earnshaw SR, McDade C, Chapman AM, Jackson D, Schwamm L. Economic impact of using additional diagnostic tests to better select patients with stroke for intravenous thrombolysis in the United Kingdom. Clin Ther. 2012 Jul 1;34(7):1544-58.

Chen S, Wu N, Boulanger L, Sacco P. Economic burden of refractory epilepsy with partial onset seizures: an assessment of direct health care resource use and costs. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A143.

Farkouh RA, Wilson MR, Tarrants ML, Castelli-Haley J, Armand C. Cost-effectiveness of rasagiline compared with first-line early parkinson disease therapies. Am J Manag Care. 2012 May 1;4(3):99-107.

Earnshaw SR. Assessing economic value and application to stroke imaging. Presented at the 50th Annual Meeting and Symposium of the American Society of Neuroradiology; April 2012.

Coon CD, Fehnel SE, Davis KH, Runken MC, Beach ME, Cady RK. The development of a survey to measure completeness of response to migraine therapy. Headache. 2012 Apr 1;52(4):550-72.

Arnold LM, Williams DA, Hudson JI, Martin SA, Clauw DJ, Crofford LJ, Wang F, Emir B, Lai C, Zablocki R, Mease PJ. Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum. 2012 Mar 1;64(3):885-94.

Alwin J, Brodtkorb T. Could the choice of patient versus proxy ratings for assessing quality of life in dementia affect resource allocation in health care? Farmeconomia e percorsi terapeutici / in collaborazione con sifeit--società italiana per studi di economia ed etica sul farmaco e sugli interventi terapeutici. 2012;13(1):25-31.

Gonzalez J, Johnson R, Runken MC, Poulos C. Generalized healthy-time equivalents for migraine-treatment outcomes from choice-experiment trade-off preferences. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 9, 2011.

Martin SA, Coon CD, McLeod LD, Chandran A, Arnold L. Study of the measurement properties of the Arnold fibromyalgia diagnostic screen: results from a cross-sectional study. Presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals; November 2011.

Johannes C, Andrews E, McQuay L, Frohlich M, Sims R. Incidence of cerebrovascular accidents in men with prostate cancer. Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 18, 2011. Chicago, IL. [abstract] Pharmacoepidemiol Drug Saf. 2011 Aug; 20(S1):S271-2.

Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, Martin SA. Toward development of a fibromyalgia responder index and disease activity score: oMERACT module update. J Rheumatol. 2011 Jul 1;38(7):1487-95.

Wu N, Chen S, Boulanger L, Fraser K, Sacco P. Incidence, prevalence, and antiepileptic drug treatment patterns of patients with refractory partial onset seizures. Poster presented at the American Epilepsy Society; June 2011. Baltimore, MD.

Meyers JL, Davis KL, Yu YF. Stroke and transient ischemic attack in the long-term care setting: patient characteristics, medication treatment, and length of stay. Consult Pharm. 2011 Mar 1;26(3):170-81.

Fehnel SE, Manjunath R, Ervin CM, French JA, Vanlandingham K, Sweeney CT. Developing a functional status diary for epilepsy. Poster presented at the 64th Annual Meeting of the American Epilepsy Society; December 1, 2010.

McKenna SP, Doward LC, Twiss J, Hagell P, Oprandi NC, Fisk J, Grand'Maison F, Bhan V, Arbizu T, Brassat D, Kohlmann T, Meads DM, Eckert BJ. International development of the Patient-Reported Outcome Indices for Multiple Sclerosis (PRIMUS). Value Health. 2010 Dec 1;13(8):946-51.

Vinceti M, Bonvicini F, Rothman KJ, Vescovi L, Wang FY. The relation between amyotrophic lateral sclerosis and inorganic selenium in drinking water: a population-based case-control study. Environ Health. 2010 Dec 1;9(Art. No. 77).

Arana A, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. Authors reply. N Engl J Med. 2010 Nov 4;363(19):1873-4.

Meyers J, Candrilli SD. Patient characteristics and charges associated with emergency department visits among patients with a diagnosis of restless legs syndrome. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. [abstract] Value Health. 2010 Nov; 13(7):A390.

Twiss J, Doward LC, McKenna SP, Eckert B. Interpreting scores on multiple sclerosis-specific patient reported outcome measures (the PRIMUS and U-FIS). Health Qual Life Outcomes. 2010 Oct 1;8:117.